[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341940-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341940-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-phase-1-study-of-biweekly-nab-paclitaxeloxaliplatins-1lv-for-advanced-upper-gastrointestinal-cancers-tcogt1216-study","A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers - TCOGT1216 study","","Oxaliplatin- and fluoropyrimidine-based triplet regimens have shown feasibility and efficacy in upper gastrointestinal (UGI) cancers. This phase 1 study assesses the feasibility and preliminary efficacy of biweekly nab-paclitaxel plus oxaliplatin and S-1/leucovorin (SOLAR) in chemo-naive UGI cancers. A 3+3 design determines maximal tolerated dose (MTD) with key endpoints including ORR, PFS, OS, and safety.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-phase-1-study-of-biweekly-nab-paclitaxeloxaliplatins-1lv-for-advanced-upper-gastrointestinal-cancers-tcogt1216-study/341940/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-phase-1-study-of-biweekly-nab-paclitaxeloxaliplatins-1lv-for-advanced-upper-gastrointestinal-cancers-tcogt1216-study/341940.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the phase 1 TCOGT1216 study?","Question",{"text":63,"@type":64},"The study determined the maximal tolerated dose (MTD) of oxaliplatin in the SOLAR regimen and evaluated secondary endpoints including ORR, PFS, OS, and safety.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which treatment-related toxicities were most common in the MTD cohort?",{"text":68,"@type":64},"The most common grade 3/4 treatment-related toxicities were neutropenia (57.9%) and diarrhea (21.1%), with dose-limiting toxicity of grade 3 diarrhea occurring at the relevant level.",{"name":70,"@type":61,"acceptedAnswer":71},"What preliminary efficacy did SOLAR show for advanced UGI cancers?",{"text":72,"@type":64},"Across intention-to-treat patients, the ORR was 63.2% with partial response in 12 patients, and median PFS and OS were 12.5 and 24.7 months, respectively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341940,1790183702,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","A phase 1 study of biweekly nab-paclitaxel/ oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers:TCOGT1216 study  \nHui-Jen Tsai1,2,3, Shih-Hung Yang4, Chin-Fu Hsiao5, Hsiang-Fong Kao4,6, Yung-Yeh Su1,2,3,7,  \nYan-Shen Shan8, Chia-Jui Yen2, Jeng-Shiun Du3, Chiun Hsu4, I-Chen Wu7,9, Li-Tzong Chen1,2,7,9,*,‡  \n1 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan  \n2Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan  \n4Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan  \n5 Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan 6 National Taiwan University Cancer Center, Taipei, Taiwan  \n7Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan  \n8Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 9Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan  \n* Corresponding author: Li-Tzong Chen, MD, PhD, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, 17ES, No 100, Tzyou 1st Road, Kaohsiung 80756, Taiwan ([leochen@nhri.org.tw](leochen@nhri.org.tw)) .  \n‡Principal Investigator: Li-Tzong Chen.  \nAbstract  \nBackground: Oxaliplatin- and fluoropyrimidine-based triplet regimens have demonstrated feasibility and efficacy in the treatment of upper gastrointestinal (UGI) cancers. Herein, we evaluate the feasibility and preliminary efficacy of biweekly nab-paclitaxel plus oxaliplatin and S-1/ leucovorin (SOLAR) in chemonaïve UGI cancers.  \nMethods: A 3 + 3 phase 1 study was conducted to determine the maximal tolerated dose (MTD) of oxaliplatin in SOLAR (nab-paclitaxel [150 mg/m2 in D1], oxaliplatin [60, 75, or 85 mg/m2 in D1], and oral S-1/leucovorin [35 mg/m2 and 30 mg bid from D1 to D7]) . The secondary endpoints were overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.  \nResults: Thirteen and 6 accruals were in the dose-escalation and MTD expansion cohorts, respectively. One of 6 patients at level III experienced dose-limiting toxicity (grade 3 diarrhea), which revealed that the MTD of oxaliplatin was 85 mg/m2. After a mean of 15.9 cycles of treatment, the most common treatment-related grade 3/4 toxicities were neutropenia (57.9%) and diarrhea (21. 1%) . The ORR was 63.2% . The median PFS and OS were 12.5 and 24.7 months, respectively.  \nConclusion: The current study revealed the MTD of oxaliplatin and demonstrated the preliminary efficacy of SOLAR in UGI cancers, which deserves further investigation.  \n[ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03162510  \nKey words: phase 1; nab-paclitaxel; oxaliplatin; S-1/leucovorin; upper gastrointestinal cancers.  \nLessons Learned  \n• Replacement of 48-hour infusion of 5-FU/LV with oral S-1/LV improves the convenience of treatment administration.  \n• The maximal tolerated dose of oxaliplatin was determined to be dose level 3 (85 mg/m2) when combined with nab-placlitaxel (150 mg/ m2) and S-1 (35 mg/m2 bid)/LV (30 mg bid) .  \n• Triplet combination of biweekly nab-paclitaxel, oxaliplatin, and S-1/LV has manageable toxicities and promising efficacy.  \nDiscussion  \nThe current phase 1 trial defined the MTD of oxaliplatin to be 85 mg/m2 of a biweekly triplet nab-paclitaxel plus oxaliplatin  \nand oral S-1/leucovorin (LV) regimen for UGI cancers (gastric cancer [GC], pancreatic cancer [PC], and biliary tract cancer [BTC]) .  \nReceived: 29 September 2023; Accepted: 19 April 2024.  \n© The Author(s) 2024. Published by Oxford University Press.  \nThis is an Open Access ","cbCaiorV054ZswJ3","https://ap.wps.com/l/cbCaiorV054ZswJ3","pdf",8421267,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Lessons Learned\n# Discussion\n# Publication Details","[{\"question\":\"What was the main goal of the phase 1 TCOGT1216 study?\",\"answer\":\"The study determined the maximal tolerated dose (MTD) of oxaliplatin in the SOLAR regimen and evaluated secondary endpoints including ORR, PFS, OS, and safety.\"},{\"question\":\"Which treatment-related toxicities were most common in the MTD cohort?\",\"answer\":\"The most common grade 3/4 treatment-related toxicities were neutropenia (57.9%) and diarrhea (21.1%), with dose-limiting toxicity of grade 3 diarrhea occurring at the relevant level.\"},{\"question\":\"What preliminary efficacy did SOLAR show for advanced UGI cancers?\",\"answer\":\"Across intention-to-treat patients, the ORR was 63.2% with partial response in 12 patients, and median PFS and OS were 12.5 and 24.7 months, respectively.\"}]","A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers - TCOGT1216 study | PDF",1790044423,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7337873c43db280d1f1d4ae893828998.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad7d9d99d729908a606a66aa38563e9f.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/391ca649cc280f40d1907e77afb9b11a.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1361d8700b643bf06bd3acb48cf3cc4.webp",980,1287]